OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SDSP55

SDS Optic SA

Biotechnology & Medical ResearchVerified

SDS Optic SA exhibits a weak capital structure and liquidity position, with a current ratio of 0.94, indicating that its current liabilities exceed its current assets. The company has no long-term debt, but its operating cash flow of -2.71 million PLN and free cash flow of -2.39 million PLN suggest significant cash outflows from operations. The debt-to-equity ratio is 0.0, reflecting no leverage in its capital structure. Profitability metrics are deeply negative, with a return on equity of -98.61% and a return on assets of -15.48%, both far below the typical thresholds for a viable business. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's revenue is reported as 0.0 PLN, and its gross profit is negative at -121,490 PLN, suggesting that it is not currently generating revenue from its operations and is incurring significant production or service delivery costs. The operating income of -2.49 million PLN and net income of -2.49 million PLN further underscore the company's unprofitable operations. There is no disclosed segment or geographic revenue breakdown in the available data, making it difficult to assess the company's exposure to different markets or product lines. The absence of revenue concentration data limits the ability to evaluate the company's diversification and risk profile. The company's growth trajectory is not evident from the data, as there is no revenue history provided to assess trends over time. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and unprofitable operations suggest a high operational risk. There are no recent events, filings, or transcripts provided in the available data to inform the company's current strategic direction or operational developments.

30-day price · SDS-8.34 (-12.9%)
Low$56.29High$65.28Close$56.38As of28 May, 00:00 UTC
Profile
CompanySDS Optic SA
TickerSDSP.WA
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. SDS Optic SA is a company engaged in healthcare diagnostics, providing products and services related to the detection and analysis of health conditions.

Classification. SDS Optic SA is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.

SDS Optic SA exhibits a weak capital structure and liquidity position, with a current ratio of 0.94, indicating that its current liabilities exceed its current assets. The company has no long-term debt, but its operating cash flow of -2.71 million PLN and free cash flow of -2.39 million PLN suggest significant cash outflows from operations. The debt-to-equity ratio is 0.0, reflecting no leverage in its capital structure. Profitability metrics are deeply negative, with a return on equity of -98.61% and a return on assets of -15.48%, both far below the typical thresholds for a viable business. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's revenue is reported as 0.0 PLN, and its gross profit is negative at -121,490 PLN, suggesting that it is not currently generating revenue from its operations and is incurring significant production or service delivery costs. The operating income of -2.49 million PLN and net income of -2.49 million PLN further underscore the company's unprofitable operations. There is no disclosed segment or geographic revenue breakdown in the available data, making it difficult to assess the company's exposure to different markets or product lines. The absence of revenue concentration data limits the ability to evaluate the company's diversification and risk profile. The company's growth trajectory is not evident from the data, as there is no revenue history provided to assess trends over time. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and unprofitable operations suggest a high operational risk. There are no recent events, filings, or transcripts provided in the available data to inform the company's current strategic direction or operational developments.
Key takeaways
  • SDS Optic SA is currently unprofitable, with a return on equity of -98.61% and a return on assets of -15.48%.
  • The company has no long-term debt but is experiencing significant negative cash flows from operations.
  • Revenue is reported as 0.0 PLN, and the company is incurring a gross loss of 121,490 PLN.
  • There is no segment or geographic revenue data available, limiting the understanding of the company's market exposure.
  • The company's liquidity position is weak, with a current ratio of 0.94.
  • No immediate liquidity or dilution risks were detected in the risk assessment.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyPLN
Revenue$0.00
Gross profit-$121.5k
Operating income-$2.5M
Net income-$2.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$2.7M
CapEx-$43.3k
Free cash flow-$2.4M
Total assets$16.1M
Total liabilities$13.6M
Total equity$2.5M
Cash & equivalents
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$451.3k-$865.8k-$1.5M-$1.5M
FY-3$849.1k-$3.4M-$3.9M-$6.8M
FY-2$3.8M-$3.9M-$3.5M-$3.4M
FY-1$5.4M-$4.1M-$5.1M-$4.9M
FY0$3.7M-$2.2M-$3.0M-$2.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$10.3M$9.9M
FY-3$7.9M$6.4M
FY-2$9.4M$8.6M
FY-1$17.5M$3.5M
FY0$16.2M$1.2M
PeriodOCFCapExFCFSBC
FY-4-$2.8M-$231.8k-$1.5M
FY-3-$5.1M-$2.9M-$6.8M
FY-2-$10.0M-$422.4k-$3.4M
FY-1-$8.4M-$437.8k-$4.9M
FY0-$7.1M-$350.1k-$2.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$0.00-$2.5M-$2.5M-$2.4M
FQ-6$0.00-$2.4M-$2.6M-$2.7M
FQ-5$150.00-$2.0M-$2.1M-$2.2M
FQ-4$5.4M$2.8M$2.2M$2.4M
FQ-3$1.3M-$760.3k-$737.4k-$912.1k
FQ-2$566.6k-$712.6k-$1.1M-$938.9k
FQ-1$256.0k-$516.8k-$827.9k-$634.3k
FQ0$936.9k-$228.5k-$319.5k-$127.3k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$16.1M$2.5M
FQ-6$13.5M-$323.1k
FQ-5$11.2M-$2.5M
FQ-4$17.5M$3.5M
FQ-3$17.0M$3.3M
FQ-2$16.2M$1.6M
FQ-1$15.9M$954.8k
FQ0$16.2M$1.2M
PeriodOCFCapExFCFSBC
FQ-7-$2.7M-$43.3k-$2.4M
FQ-6-$4.7M-$223.5k-$2.7M
FQ-5-$6.5M-$434.1k-$2.2M
FQ-4-$8.4M-$437.8k$2.4M
FQ-3-$2.1M-$350.1k-$912.1k
FQ-2-$3.9M-$350.1k-$938.9k
FQ-1-$5.5M-$350.1k-$634.3k
FQ0-$7.1M-$350.1k-$127.3k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.5M
Net cash
Current ratio0.9
Debt/Equity0.0
ROA-15.5%
ROE-98.6%
Cash conversion1.1%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricSDSPActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 02:31 UTC#664753df
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 08:51 UTCJob: 254a2727